Overview
Compare with Zepp Health, Supermicro or One Stop Systems, Inc., or pick any stock.
- TickerOMCL on Nasdaq1
- IndustryElectronic Computers1
- HeadquartersFort Worth, Texas1
- Incorporated inDE2
- Business address4220 North Freeway, Fort Worth, Tx 761372
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
Omnicell, a leading healthcare technology provider focused on empowering autonomous medication management, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery. Omnicell is focused on helping its customers define and deliver a cost-effective medication management strategy designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. We are doing this with an industry-leading medication management infrastructure which includes storage and dispensing automation powered by an intelligence ecosystem. Our comprehensive set of solutions provides the critical foundation for customers to realize the Autonomous Pharmacy, an indust…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
42.5%Gross margin5
0.4%Operating margin5
0.2%Net margin5
6.5%Revenue growth, 20255
0.2%Return on equity5
$86.9MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Connected Devices, Software Licenses, And Other brought in 48% of the revenue OMNICELL, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Connected Devices, Software Licenses, And Other | $623.6M | $539.2M | $565.5M |
| Technical Services | $225.8M | $238.2M | $260.1M |
| SaaS and Expert Services | $212.7M | $243.5M | $259.1M |
| Consumables | $85.0M | $91.3M | $100.2M |
Regions
United States brought in 90% of the revenue OMNICELL, INC. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.0B | $1.0B | $1.1B |
| Outside the United States | $135.7M | $99.9M | $119.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue57¢$681.4M
- Research and development7¢$88.7M
- Selling, general and admin34¢$409.6M
- Income tax1¢$9.3M
- Profit0¢$2.1M
Out of $1.2B in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending32¢$40.4M
- Share buybacks61¢$77.6M
- Kept or used elsewhere7¢$9.3M
Out of $127.3M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $1.2B | $1.1B | $1.1B |
| Cost of revenues | $681.4M | $641.2M | $650.3M |
| Gross profit | $503.4M | $471.0M | $496.8M |
| Research and development | $88.7M | $90.4M | $97.1M |
| Selling, general, and administrative | $409.6M | $380.3M | $434.6M |
| Total operating expenses | $498.3M | $470.7M | $531.7M |
| Income (loss) from operations | $5.2M | $337.0K | -$34.9M |
| Interest and other income (expense), net | $6.2M | $25.3M | $14.8M |
| Income (loss) before income taxes | $11.3M | $25.6M | -$20.1M |
| Provision for income taxes | $9.3M | $13.1M | $263.0K |
| Net income (loss) | $2.1M | $12.5M | -$20.4M |
| Basic (in dollars per share) | $0.04 | $0.27 | -$0.45 |
| Diluted (in dollars per share) | $0.04 | $0.27 | -$0.45 |
| Basic (in shares) | 46.0M shares | 46.0M shares | 45.2M shares |
| Diluted (in shares) | 46.4M shares | 46.3M shares | 45.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $196.5M | $369.2M | $468.0M | |
| Accounts receivable and unbilled receivables, net of allowances of $8,868 and $6,645, respectively | $216.9M | $256.4M | ||
| Inventories | $100.9M | $88.7M | ||
| Prepaid expenses | $33.7M | $25.9M | ||
| Other current assets | $132.1M | $75.3M | ||
| Total current assets | $680.1M | $815.5M | ||
| Property and equipment, net | $120.1M | $112.7M | ||
| Long-term investment in sales-type leases, net | $60.7M | $52.7M | ||
| Operating lease right-of-use assets | $24.4M | $25.6M | ||
| Goodwill | $737.9M | $734.7M | $735.8M | |
| Intangible assets, net | $170.1M | $188.3M | ||
| Long-term deferred tax assets | $58.3M | $57.5M | ||
| Prepaid commissions | $52.8M | $54.7M | ||
| Other long-term assets | $70.2M | $79.3M | ||
| Total assets | $2.0B | $2.1B | ||
| Accounts payable | $44.0M | $51.8M | ||
| Accrued compensation | $57.2M | $60.3M | ||
| Accrued liabilities | $203.6M | $167.9M | ||
| Deferred revenues | $171.9M | $141.4M | ||
| Convertible senior notes, net | $0 | $174.3M | ||
| Total current liabilities | $476.6M | $595.7M | ||
| Long-term deferred revenues | $63.3M | $76.1M | ||
| Long-term deferred tax liabilities | $683.0K | $1.1M | ||
| Long-term operating lease liabilities | $24.8M | $31.1M | ||
| Other long-term liabilities | $10.0M | $7.2M | ||
| Convertible senior notes, net, noncurrent | $167.6M | $166.4M | ||
| Total liabilities | $742.9M | $877.6M | ||
| Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued | $0 | $0 | ||
| Common stock, $0.001 par value, 100,000 shares authorized; 57,833 and 56,665 shares issued; 45,027 and 46,382 shares outstanding, respectively | $58.0K | $57.0K | ||
| Treasury stock at cost, 12,806 and 10,283 shares outstanding, respectively | -$368.3M | -$290.3M | ||
| Additional paid-in capital | $1.2B | $1.2B | ||
| Retained earnings | $384.9M | $382.9M | ||
| Accumulated other comprehensive loss | -$8.9M | -$17.2M | ||
| Total stockholders equity | $1.2B | $1.2B | $1.2B | $1.1B |
| Total liabilities and stockholders equity | $2.0B | $2.1B | ||
| Accounts receivable and unbilled receivables, net of allowance | $8.9M | $6.6M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued (in shares) | 57.8M shares | 56.7M shares | ||
| Common stock, shares outstanding (in shares) | 45.0M shares | 46.4M shares | ||
| Treasury stock, shares outstanding (in shares) | 12.8M shares | 10.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $196.5M | $369.2M | $468.0M | |
| Accounts receivable and unbilled receivables, net of allowances of $8,868 and $6,645, respectively | $216.9M | $256.4M | ||
| Inventories | $100.9M | $88.7M | ||
| Prepaid expenses | $33.7M | $25.9M | ||
| Other current assets | $132.1M | $75.3M | ||
| Total current assets | $680.1M | $815.5M | ||
| Property and equipment, net | $120.1M | $112.7M | ||
| Long-term investment in sales-type leases, net | $60.7M | $52.7M | ||
| Operating lease right-of-use assets | $24.4M | $25.6M | ||
| Goodwill | $737.9M | $734.7M | $735.8M | |
| Intangible assets, net | $170.1M | $188.3M | ||
| Long-term deferred tax assets | $58.3M | $57.5M | ||
| Prepaid commissions | $52.8M | $54.7M | ||
| Other long-term assets | $70.2M | $79.3M | ||
| Total assets | $2.0B | $2.1B | ||
| Accounts payable | $44.0M | $51.8M | ||
| Accrued compensation | $57.2M | $60.3M | ||
| Accrued liabilities | $203.6M | $167.9M | ||
| Deferred revenues | $171.9M | $141.4M | ||
| Convertible senior notes, net | $0 | $174.3M | ||
| Total current liabilities | $476.6M | $595.7M | ||
| Long-term deferred revenues | $63.3M | $76.1M | ||
| Long-term deferred tax liabilities | $683.0K | $1.1M | ||
| Long-term operating lease liabilities | $24.8M | $31.1M | ||
| Other long-term liabilities | $10.0M | $7.2M | ||
| Convertible senior notes, net, noncurrent | $167.6M | $166.4M | ||
| Total liabilities | $742.9M | $877.6M | ||
| Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued | $0 | $0 | ||
| Common stock, $0.001 par value, 100,000 shares authorized; 57,833 and 56,665 shares issued; 45,027 and 46,382 shares outstanding, respectively | $58.0K | $57.0K | ||
| Treasury stock at cost, 12,806 and 10,283 shares outstanding, respectively | -$368.3M | -$290.3M | ||
| Additional paid-in capital | $1.2B | $1.2B | ||
| Retained earnings | $384.9M | $382.9M | ||
| Accumulated other comprehensive loss | -$8.9M | -$17.2M | ||
| Total stockholders equity | $1.2B | $1.2B | $1.2B | $1.1B |
| Total liabilities and stockholders equity | $2.0B | $2.1B | ||
| Accounts receivable and unbilled receivables, net of allowance | $8.9M | $6.6M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued (in shares) | 57.8M shares | 56.7M shares | ||
| Common stock, shares outstanding (in shares) | 45.0M shares | 46.4M shares | ||
| Treasury stock, shares outstanding (in shares) | 12.8M shares | 10.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $2.1M | $12.5M | -$20.4M |
| Depreciation and amortization | $78.8M | $82.2M | $87.3M |
| Loss on disposal of assets | $488.0K | $978.0K | $2.6M |
| Share-based compensation expense | $44.5M | $39.3M | $55.3M |
| Deferred income taxes | -$1.3M | -$14.9M | -$11.0M |
| Amortization of operating lease right-of-use assets | $7.8M | $7.5M | $8.2M |
| Impairment and abandonment of operating lease right-of-use assets related to facilities | $0 | $0 | $10.0M |
| Impairment of external-use software development costs | $599.0K | $0 | $0 |
| Impairment of certain long-lived assets | $0 | $0 | $1.0M |
| Inventory write-down | $0 | $5.4M | $0 |
| Amortization of debt issuance costs | $2.7M | $3.8M | $4.4M |
| Gain on extinguishment of convertible senior notes, net | $0 | -$7.5M | $0 |
| Accounts receivable and unbilled receivables | $41.4M | -$5.0M | $49.1M |
| Inventories | -$11.2M | $15.6M | $38.0M |
| Prepaid expenses | -$7.8M | $24.0K | $1.1M |
| Other current assets | -$774.0K | $9.3M | -$6.8M |
| Investment in sales-type leases | -$10.2M | -$10.4M | -$10.4M |
| Prepaid commissions | $1.8M | -$2.2M | $7.1M |
| Other long-term assets | $4.1M | $2.2M | $2.1M |
| Accounts payable | -$9.3M | $7.2M | -$17.5M |
| Accrued compensation | -$4.0M | $8.6M | -$21.5M |
| Accrued liabilities | -$19.0M | $13.9M | -$10.3M |
| Deferred revenues | $16.4M | $29.0M | $24.1M |
| Operating lease liabilities | -$11.7M | -$10.7M | -$10.9M |
| Other long-term liabilities | $1.9M | $900.0K | -$401.0K |
| Net cash provided by operating activities | $127.3M | $187.7M | $181.1M |
| Asset acquisition | -$2.4M | $0 | $0 |
| External-use software development costs | -$17.5M | -$16.3M | -$13.5M |
| Purchases of property and equipment | -$40.4M | -$36.5M | -$41.5M |
| Net cash used in investing activities | -$60.4M | -$52.8M | -$55.0M |
| Payments for debt issuance costs for revolving credit facility | $0 | $0 | -$3.0M |
| Repayment of convertible senior notes due 2025 | -$175.0M | $0 | $0 |
| Proceeds from issuance of convertible senior notes, net of issuance costs | $0 | $166.3M | $0 |
| Partial repurchase of convertible senior notes | $0 | -$391.0M | $0 |
| Purchase of convertible note hedge | $0 | -$40.3M | $0 |
| Proceeds from sale of warrants | $0 | $25.2M | $0 |
| Partial unwind of convertible note hedge and warrants | $0 | -$727.0K | $0 |
| Proceeds from issuances under stock-based compensation plans | $16.9M | $13.4M | $23.2M |
| Employees taxes paid related to restricted stock units | -$7.7M | -$4.8M | -$7.4M |
| Common stock repurchases | -$77.6M | $0 | $0 |
| Change in customer funds, net | $25.1M | -$3.6M | $10.5M |
| Net cash provided by (used in) financing activities | -$218.3M | -$235.6M | $23.4M |
| Effect of exchange rate changes on cash and cash equivalents | $3.8M | -$1.7M | -$1.4M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -$147.6M | -$102.4M | $148.1M |
| Cash paid for interest | $2.2M | $1.6M | $1.4M |
| Unpaid purchases of property and equipment | $2.3M | $1.0M | $877.0K |
| Excise tax payable on common stock repurchases | $388.0K | $0 | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
OMNICELL, INC. sits at the top of its group. 6 entities, 6 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of OMNICELL, INC.
- MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on OMNICELL, INC., latest Aug 10, 2026 (2 filings since Apr 1, 2026)
- Wellington Management Company Filed SCHEDULE 13G on OMNICELL, INC., latest May 15, 2026 (4 filings since Feb 4, 2022)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on OMNICELL, INC., latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on OMNICELL, INC., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on OMNICELL, INC., latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G on OMNICELL, INC., latest Oct 9, 2025
- BlackRock Filed SCHEDULE 13G/A on OMNICELL, INC., latest Apr 28, 2025 (5 filings since Jan 26, 2022)
- OMNICELL, INC. Fort Worth, Texas
- Hub and Spoke Innovations Limited Subsidiary · United Kingdom
- Omnicell (Beijing) Technology Co. Ltd Subsidiary · China
- Omnicell India Private Limited Subsidiary · India
- Omnicell International Regional Headquarters Middle East and North Africa Subsidiary · Saudi Arabia
- Omnicell S.r.l. Subsidiary · Italy
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What OMNICELL, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $266.5M5 Dec 31, 2025 | $249.3M5 Dec 31, 2024 | +6.9% |
| Property and equipment, before depreciation | $316.7M5 Dec 31, 2025 | $281.1M5 Dec 31, 2024 | +12.7% |
| Accumulated depreciation | $196.5M5 Dec 31, 2025 | $168.4M5 Dec 31, 2024 | +16.7% |
| Property and equipment, net | $120.1M5 Dec 31, 2025 | $112.7M5 Dec 31, 2024 | +6.6% |
| Operating-lease assets (leased space) | $24.4M5 Dec 31, 2025 | $25.6M5 Dec 31, 2024 | −4.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $196.5M5 Dec 31, 2025 | $369.2M5 Dec 31, 2024 | −46.8% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $737.9M5 Dec 31, 2025 | $734.7M5 Dec 31, 2024 | +0.4% |
| Intangible assets, net (excluding goodwill) | $170.1M5 Dec 31, 2025 | $188.3M5 Dec 31, 2024 | −9.6% |
| Finite-lived intangibles, gross | $350.2M5 Dec 31, 2025 | $358.2M5 Dec 31, 2024 | −2.2% |
| Accumulated amortization | $178.8M5 Dec 31, 2025 | $168.6M5 Dec 31, 2024 | +6.0% |
| Finite-lived intangibles, net | $170.1M5 Dec 31, 2025 | $188.3M5 Dec 31, 2024 | −9.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $100.9M5 Dec 31, 2025 | $88.7M5 Dec 31, 2024 | +13.8% |
| Raw materials | $26.2M5 Dec 31, 2025 | $33.5M5 Dec 31, 2024 | −21.7% |
| Work in process | $1.3M5 Dec 31, 2025 | $1.5M5 Dec 31, 2024 | −12.8% |
| Finished goods | $73.3M5 Dec 31, 2025 | $53.6M5 Dec 31, 2024 | +36.7% |
Properties, in its own words
Our headquarters are located in a leased facility in Fort Worth, Texas. The following is a list of our material leased facilities and their primary functions:
Site · Major Activity · Approximate Square Footage
The rest of Item 2
St. Petersburg, Florida · Administration, marketing, research and development, sales, and manufacturing · 167,700
Warrendale, Pennsylvania · Manufacturing and research and development · 107,400
Cranberry Township, Pennsylvania · Administration, marketing, research and development, sales, technical support, and training · 58,400
Milpitas, California · Administration, manufacturing, and research and development · 46,300
Fort Worth, Texas · Administration, sales, marketing, and research and development · 34,400
Warrington, United Kingdom · Administration, sales, marketing, and distribution center · 19,300
We also have smaller rented facilities in Strongsville, Ohio; Austin, Texas; Grapevine, Texas; Germany; France; India; Italy; the People’s Republic of China; the United Arab Emirates; Australia; and the United Kingdom.
We believe that these facilities are sufficient for our current operational needs and that suitable additional space will be available on commercially reasonable terms to accommodate expansion of our operations, if necessary.
For additional information regarding our obligations pursuant to operating leases, refer to Note 13, Lessee Leases, of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.
Item 2 of the 10-K filed Feb 26, 2026.4
Leadership
Who has led OMNICELL, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerRandall A. Lipps Feb 7, 2006 to now14
- ChairRandall A. Lipps Mar 12, 2013 to now15
- PresidentNnamdi Njoku Jul 6, 2026 to now16
- PresidentJ. Christopher Drew Feb 8, 2018 to Jun 5, 201817
- PresidentRobin Gene Seim Feb 8, 2018 to Mar 20, 201918
- PresidentRandall A. Lipps Feb 7, 2006 to Feb 8, 201814
- Chief financial officerHarlan Baird Radford Sep 5, 2025 to now19
- Chief financial officerNchacha Etta Jun 2, 2023 to Sep 5, 202520
- Chief financial officerPeter J. Kuipers Aug 25, 2015 to Dec 19, 202221
- Chief financial officerRobin Gene Seim Feb 9, 2007 to Aug 14, 201522
- Chief operating officerNnamdi Njoku Oct 11, 2024 to now23
Board members and other officers (41)
- VP, Chief Accounting OfficerBrian H. Nutt May 17, 2024 to now24
- EVP, EXECUTIVE ADVISORPeter J. Kuipers Jun 16, 2023 to Jun 16, 202325
- EVP, EXECUTIVE ADVISORDan S. Johnston Jun 17, 2022 to Jun 17, 202226
- EVP, Chief People OfficerChristine Marie Mellon Mar 1, 2021 to Jun 12, 202327
- Chief Accounting Officer & VPJoseph Brian Spears Jan 31, 2018 to May 17, 202428
- EVP, Chief Commercial OfficerScott Peter Seidelmann Apr 10, 2018 to Jun 16, 202329
- Executive VP. EngineeringJorge R. Taborga Apr 26, 2013 to Mar 12, 201930
- Exec. VP, Global ManufacturingMichael D. Stevenson Apr 26, 2013 to Dec 18, 201331
- Executive Vice PresidentWilliam G. Shields Jun 6, 2012 to Jun 6, 201232
- Vice President, MarketingMarga Ortigas-Wedekind Jan 22, 2009 to Apr 2, 201533
- VP, Strategy & Business Dev.Nhat H. Ngo Nov 7, 2008 to Feb 18, 202134
- S.V.P. H.R. Emp. Learn & Perf.John Choma Feb 9, 2007 to Feb 6, 200935
- Executive VP/FinanceRobin Gene Seim Feb 2, 2006 to Dec 18, 201736
- Exec VP SalesGary E. Wright Mar 2, 2006 to Mar 2, 200637
- Vice President SalesRenee M. Luhr Mar 17, 2006 to Jan 6, 200938
- Vice President/MarketingBrian Robert Rodli Apr 10, 2006 to Mar 5, 200739
- EVP, Field Ops & Bus DevJ. Christopher Drew May 8, 2006 to Dec 18, 201740
- Board memberEileen J. Martinson Jan 16, 2024 to now41
- Board memberKaushik Ghoshal Jul 17, 2023 to now42
- Board memberMary Garrett May 26, 2022 to now43
- Board memberEdward Peter Bousa Jul 19, 2021 to now44
- Board memberRobin Gene Seim May 7, 2019 to now45
- Board memberBruce E. Scott May 16, 2019 to now46
- Board memberJoanne B. Bauer Jan 3, 2014 to now47
- Board memberMark W. Parrish Jan 3, 2013 to now48
- Board memberVance B. Moore May 24, 2012 to May 25, 202349
- Board memberGary S. Petersmeyer Feb 6, 2007 to May 15, 201950
- Board memberDonald C. Wegmiller Jan 27, 2006 to Aug 14, 201351
- Board memberJoseph E. Whitters Feb 7, 2006 to Nov 16, 201252
- Board memberRandall A. Lipps Feb 7, 2006 to Feb 7, 201414
- Board memberJohn D. Stobo Jr. Feb 10, 2006 to Feb 10, 200653
- Board memberSara J. White Feb 14, 2006 to May 25, 202354
- Board memberBrock Nelson May 5, 2006 to Feb 12, 200755
- Board memberKevin L. Roberg May 5, 2006 to Oct 27, 200656
- Board memberMary E. Foley May 5, 2006 to Aug 16, 201257
- Board memberRandy D. Lindholm May 5, 2006 to Oct 11, 201658
- Board memberWilliam H. Younger Jr. May 5, 2006 to Feb 17, 201259
- Board memberJames T. Judson Sep 5, 2006 to Aug 30, 202160
- General counselCorey J. Manley May 20, 2022 to now61
- General counselJohn Choma Jul 6, 2009 to Jul 6, 200962
- General counselDan S. Johnston Feb 2, 2006 to Mar 16, 202263
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Hub and Spoke Innovations Limited United Kingdom3
- Omnicell (Beijing) Technology Co. Ltd China3
- Omnicell GmbH Germany3
- Omnicell India Private Limited India3
- Omnicell International Regional Headquarters Middle East and North Africa Saudi Arabia3
- Omnicell Limited United Kingdom3
- Omnicell Pty Ltd Australia3
- Omnicell S.r.l. Italy3
- Omnicell SAS France3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Jul 30, 20268-K Results of operations64
- Jul 1, 20268-K Executive or director change65
- May 26, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote66
- Apr 28, 20268-K Results of operations67
- Feb 5, 20268-K Results of operations68
- Dec 8, 20258-K Regulation FD disclosure69
- Oct 30, 20258-K Results of operations70
- Oct 6, 20258-K Bylaws or fiscal year changed71
- Aug 25, 20258-K Executive or director change72
- Jul 31, 20258-K Results of operations73
- Jun 5, 20258-K Executive or director change74
- May 23, 20258-K Executive or director change; Shareholder vote75
- Feb 7, 2006New chief executive Randall A. Lipps becomes CEO14
Calendar
Coming up
- Oct 29, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.32 a share, on Oct 30, 2025.76
When it reported results
- Jul 30, 2026Reported quarterly or annual results64
- Apr 28, 2026Reported quarterly or annual results67
- Feb 5, 2026Reported quarterly or annual results68
- Oct 30, 2025Reported quarterly or annual results70
- Jul 31, 2025Reported quarterly or annual results73
- May 6, 2025Reported quarterly or annual results77
- Feb 6, 2025Reported quarterly or annual results78
- Oct 30, 2024Reported quarterly or annual results79
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
348 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 213 insider forms, 19 large holders, 35 other. The latest 20:
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 10, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Jul 30, 20268-K EDGAR
- Jul 17, 20264 EDGAR
- Jul 15, 2026144 EDGAR
- Jul 7, 2026S-8 EDGAR
- Jul 6, 20264 EDGAR
- Jul 1, 20268-K EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
The 348 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
34 open-market trades by officers, directors and large owners since October 2021: 2 buys and 32 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Njoku NnamdiPresident & COO | Sale | 3,083 | $36.85 | $113.6K | Form 4 |
| Jul 15, 2026 | LIPPS RANDALL ACHAIRMAN, CEO | Sale | 10,000 | $47.00 | $470.0K | Form 4 |
| May 18, 2026 | Njoku NnamdiPresident & COO | Sale | 3,090 | $43.22 | $133.6K | Form 4 |
| May 18, 2026 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 5,025 | $43.22 | $217.2K | Form 4 |
| Mar 16, 2026 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 7,405 | $34.69 | $256.9K | Form 4 |
| Feb 17, 2026 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 4,243 | $36.59 | $155.3K | Form 4 |
| Jan 8, 2026 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 6,106 | $49.90 | $304.7K | Form 4 |
| Dec 16, 2025 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 278 | $43.30 | $12.0K | Form 4 |
| Dec 3, 2025 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 6,106 | $39.90 | $243.6K | Form 4 |
| Dec 1, 2025 | LIPPS RANDALL ACHAIRMAN, CEO | Sale | 28,250 | $35.97 | $1.0M | Form 4 |
| Nov 17, 2025 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 3,473 | $34.90 | $121.2K | Form 4 |
| Sep 12, 2025 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Sale | 3,880 | $33.25 | $129.0K | Form 4 |
| Mar 14, 2025 | LIPPS RANDALL ACHAIRMAN, CEO | Buy | 10,561 | $33.13 | $349.9K | Form 4 |
| Dec 10, 2024 | PARRISH MARK WDirector | Sale | 12,000 | $47.30 | $567.6K | Form 4 |
| Jun 9, 2023 | MELLON CHRISTINE MARIEEVP, EXECUTIVE ADVISOR | Sale | 7,951 | $73.14 | $581.5K | Form 4 |
| Jun 8, 2023 | LIPPS RANDALL ACHAIRMAN, CEO | Buy | 4,000 | $73.76 | $295.0K | Form 4 |
| Mar 7, 2023 | Bauer Joanne BDirector | Sale | 13,115 | $54.24 | $711.4K | Form 4 |
| Dec 27, 2022 | Seidelmann Scott PeterEVP, EXECUTIVE ADVISOR | Sale | 945 | $48.28 | $45.6K | Form 4 |
| Dec 16, 2022 | Seidelmann Scott PeterEVP, EXECUTIVE ADVISOR | Sale | 4,436 | $47.79 | $212.0K | Form 4 |
| Dec 1, 2022 | LIPPS RANDALL ACHAIRMAN, CEO | Sale | 2,500 | $50.78 | $126.9K | Form 4 |
All 34 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 1, 2026 to Aug 10, 202680
- Wellington Management CompanySCHEDULE 13G, 4 filings Feb 4, 2022 to May 15, 202681
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202682
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202683
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202684
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G, 1 filing Oct 9, 202585
- BlackRockSCHEDULE 13G/A, 5 filings Jan 26, 2022 to Apr 28, 202586
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Randall A. LippsChairman, President and Chief Executive Officer | $846.9K | $7.5M87 | |
| 2025 | Nnamdi T. NjokuExecutive Vice President, Chief Operating Officer | $645.0K | $4.0M87 | |
| 2025 | Corey J. ManleyExecutive Vice President, Chief Legal and Administrative Officer | $416.6K | $2.5M87 | |
| 2025 | Nchacha E. EttaFormer Executive Vice President, Chief Financial Officer | $449.4K | $2.0M87 | |
| 2025 | H. Baird Radford, IIIExecutive Vice President, Chief Financial Officer | $159.5K | $1.5M87 | |
| 2024 | Randall A. LippsChairman, President and Chief Executive Officer | $822.5K | $8.2M87 | |
| 2024 | Nchacha E. EttaFormer Executive Vice President, Chief Financial Officer | $480.5K | $3.1M87 | |
| 2024 | Nnamdi T. NjokuExecutive Vice President, Chief Operating Officer | $124.0K | $2.7M87 | |
| 2024 | Corey J. ManleyExecutive Vice President, Chief Legal and Administrative Officer | $404.6K | $2.7M87 | |
| 2023 | Randall A. LippsChairman, President and Chief Executive Officer | $813.1K | $11.0M87 | |
| 2023 | Nchacha E. EttaFormer Executive Vice President, Chief Financial Officer | $259.4K | $5.2M87 | |
| 2023 | Corey J. ManleyExecutive Vice President, Chief Legal and Administrative Officer | $386.9K | $3.1M87 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 7,539,602 | $313.0M | 0.0% | +332,384 |
| Vanguard Portfolio Management LLC | 3,151,350 | $130.8M | 0.0% | −63,416 |
| Wellington Management Group Llp | 2,700,603 | $112.1M | 0.0% | −6,443 |
| Dimensional Fund Advisors LP | 2,452,443 | $101.8M | 0.0% | +2,058 |
| State Street Corp | 2,085,723 | $86.6M | 0.0% | +135,184 |
| Vanguard Capital Management LLC | 1,970,472 | $81.8M | 0.0% | +35,955 |
| Millennium Management LLC | 1,734,375 | $72.0M | 0.1% | −554,195 |
| Nomura Asset Management International Inc. | 1,606,404 | $66.7M | 0.1% | +422,787 |
| Geode Capital Management, LLC | 1,216,652 | $50.5M | 0.0% | +74,189 |
| Nuveen, LLC | 1,028,896 | $42.7M | 0.0% | +640,248 |
| Arrowstreet Capital, Limited Partnership | 912,623 | $37.9M | 0.0% | +633,255 |
| Bank Of America Corp /de/ | 900,777 | $37.4M | 0.0% | +319,902 |
| Two Sigma Investments, LP | 794,781 | $33.0M | 0.0% | −257,020 |
| Charles Schwab Investment Management Inc | 639,443 | $26.5M | 0.0% | −14,722 |
| Morgan Stanley | 605,475 | $25.1M | 0.0% | −11,141 |
| Renaissance Technologies LLC | 596,243 | $24.8M | 0.0% | +113,200 |
| Royal Bank Of Canada | 574,235 | $23.8M | 0.0% | +42,063 |
| Goldman Sachs Group Inc | 540,435 | $22.4M | 0.0% | +187,038 |
| Boston Partners | 518,159 | $21.9M | 0.0% | −13,146 |
| Northern Trust Corp | 511,216 | $21.2M | 0.0% | +34,131 |
| Ameriprise Financial Inc | 486,490 | $20.2M | 0.0% | +202,031 |
| Bank of New York Mellon Corp | 466,994 | $19.4M | 0.0% | +33,540 |
| First Light Asset Management, LLC | 452,324 | $18.8M | 1.1% | −37,522 |
| Jacobs Levy Equity Management, Inc | 446,639 | $18.5M | 0.1% | −56,061 |
| Qube Research & Technologies Ltd | 433,722 | $18.0M | 0.0% | +121,266 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Apr 9, 2021 | Sara JacobsDemocratic, House | Sale | $50,001 - $100,000 | +160.9% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How OMNICELL, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAROMNICELL, INC.1
- CIK0000926326
- Employer ID (EIN)94-31664584
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3571 Electronic Computers1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address4220 North Freeway, Fort Worth, TX 761371
- Phone87741599901
- Shares outstanding45,614,884 as of Jul 29, 202611
- Public float$1.3B as of Jun 30, 20254
- AuditorDeloitte & Touche LLP, San Jose, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceApr 20, 20001
- Filings2,100 in all: 4 (1,371), 8-K (250), SC 13G/A (85), 10-Q (76), 4/A (56), SC 13G (35), 3 (33), DEF 14A (26)1
All 38 form types
10-K (24), S-8 (21), 144 (15), UPLOAD (15), CORRESP (13), SD (13), 8-K/A (10), ARS (8), 3/A (6), SCHEDULE 13G (5), 424B5 (4), S-1/A (4), 10-Q/A (3), 5 (3), PRE 14A (3), SCHEDULE 13G/A (3), 10-K/A (2), DEFA14A (2), NT 10-K (2), S-1 (2), 10-K405 (1), 424A (1), 424B4 (1), 8-A12G (1), DEFR14A (1), PRER14A (1), RW (1), S-3 (1), S-3/A (1), S-3ASR (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 13, 2026
Latest 8-K (8-K) Jul 30, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value | OMCL | NASDAQ Global Select Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks OMNICELL, INC. names in Item 1A of its 10-K filed Feb 26, 2026: 49 risks under these headings, as written.4
- Risks Related to Ownership of Our Common Stock
- Risks Related to Our Notes
- General Risks
- Unfavorable economic and market conditions and a decreased demand in the capital equipment market could adversely affect our business, operating results, cash flow, or financial condition.
- We may fail to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner, or our new or enhanced solutions may not achieve market acceptance.
- Failure to generate new sales and any reduction in the demand for, or adoption of, our medication management solutions, medication packaging systems, or related services would reduce our revenues.
- If we fail to achieve anticipated growth targets or market adoption, our business could be adversely affected.
- Delays in installations of our medication management solutions, including our central pharmacy automation solutions, could harm our competitive position, operating results, and financial condition.
- Periods of significant volatility due to geopolitical developments could adversely impact our business, operating results, cash flow, or financial condition.
- We may face increased credit, collection, and operational risks associated with providing lease financing options to our customers.
- Significant disruptions in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, could adversely impact our business.
- We may incorporate artificial intelligence technologies into certain of our products, services and processes or our vendors may incorporate artificial intelligence tools into their offerings. These technologies are new and developing and may present operational, financial, compliance, and reputational risks, as well as other adverse consequences to our business.
The other 40 risks
- If errors occur during the provision of certain of our SaaS and Expert Services, or if we fail to maintain expected service levels, we may be liable to our customers or third parties which may result in a decline in our SaaS and Expert Services offerings revenue.
- We may not be able to retain our SaaS and Expert Services customers.
- If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
- If we are unable to meet the demands of, or maintain our relationships with, our institutional and retail pharmacy customers, our revenue from sales of medication packages, other consumables, or our SaaS and Expert Services may decline.
- Our inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers could have a material adverse effect on our business.
- We operate in highly competitive markets, and we may be unable to compete successfully.
- The transition to selling more SaaS and Expert Services, which include a software as a service or solution as a service subscription, presents a number of risks.
- We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.
- We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.
- We may fail to realize the potential benefits of acquired businesses, which could negatively affect our business, operating results, cash flow, or financial condition.
- If goodwill or other intangible assets that we recorded in connection with our prior acquisitions become impaired, we could be required to take significant charges against earnings.
- The healthcare industry is subject to legislative and regulatory changes, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
- Government regulation of the healthcare industry could reduce demand for our products or services, or substantially increase the cost to produce our products or deliver our services.
- Changes to the 340B Program could negatively impact our business.
- We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations.
- Our international operations and international supply chain may subject us to additional risks that can adversely affect our business, operating results, cash flow, or financial condition.
- Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and operating results could be adversely affected.
- The concentration of our cash and cash equivalents with a limited number of financial institutions may expose us to liquidity and counterparty risk.
- Climate change, legal, regulatory or market measures to address climate change and a focus on environmental, social and corporate governance (“ESG”) matters by various stakeholders may negatively affect our business and operating results.
- Catastrophic events may disrupt our business and harm our operating results.
- Our success is dependent on our ability to recruit and retain skilled and motivated personnel.
- Our failure to protect our intellectual property rights could negatively affect our ability to compete.
- Our products use raw materials and components that may be subject to price fluctuations, shortages, or interruptions of supply, and if we are unable to maintain supply sources for such raw materials and components, or if such sources fail to satisfy our supply requirements, in particular with regard to semiconductor chips, we may experience a loss of sales, increased component costs, and reduced profitability.
- We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.
- Our U.S. government lease agreements are subject to annual budget funding cycles and mandated changes, which may affect our ability to recognize revenues and sell receivables based on such leases.
- If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
- Intellectual property claims against us could harm our competitive position, operating results, and financial condition.
- Product liability claims against us could harm our competitive position, operating results, and financial condition.
- We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
- Investment in new business strategies, initiatives, products or solutions could disrupt ongoing business and present risks not originally contemplated.
- The market price of our common stock may continue to be highly volatile.
- Our quarterly and annual operating results may fluctuate, which makes our future operating results difficult to predict, and may cause our stock price to decline.
- If financial or industry analysts have difficulty understanding changes to our business model, or we fail to meet (or significantly exceed) our publicly announced financial guidance, our stock price and trading volume could decline.
- Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, operating results, cash flow, or financial condition.
- Certain provisions in our charter documents and under Delaware law may discourage, delay, or prevent an acquisition of us and limit our stockholders’ ability to obtain a favorable judicial forum for certain disputes.
- Conversion of the 2029 Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.
- The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect our financial condition and operating results.
- The convertible note hedge and warrant transactions may affect the value of our common stock.
- General Risk Factors
- Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business, operating results, cash flow, or financial condition.
- Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
Legal proceedings
Refer to the information set forth under “Legal Proceedings” in Note 14, Commitments and Contingencies, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAROMNICELL, INC. filings on SEC EDGAR
- 2SEC EDGAROMNICELL, INC. filings on SEC EDGAR
- 3
- 4
- 5SEC EDGAROMNICELL, INC. 10-K for fiscal 2025
- 6SEC EDGAROMNICELL, INC. 10-K for fiscal 2019
- 7SEC EDGAROMNICELL, INC. 10-K for fiscal 2020
- 8SEC EDGAROMNICELL, INC. 10-K for fiscal 2021
- 9SEC EDGAROMNICELL, INC. 10-K for fiscal 2022
- 10SEC EDGAROMNICELL, INC. 10-Q for fiscal 2026
- 11SEC EDGAROMNICELL, INC. 10-Q for fiscal 2026
- 12SEC EDGAROMNICELL, INC. 10-K for fiscal 2019
- 13SEC EDGAROMNICELL, INC. 10-K for fiscal 2019
- 14
- 15SEC EDGARRandall A. Lipps, Chair
- 16SEC EDGARNnamdi Njoku, President
- 17SEC EDGARJ. Christopher Drew, President
- 18SEC EDGARRobin Gene Seim, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37SEC EDGARGary E. Wright, Exec VP Sales
- 38SEC EDGARRenee M. Luhr, Vice President Sales
- 39
- 40
- 41SEC EDGAREileen J. Martinson, Board member
- 42SEC EDGARKaushik Ghoshal, Board member
- 43SEC EDGARMary Garrett, Board member
- 44SEC EDGAREdward Peter Bousa, Board member
- 45SEC EDGARRobin Gene Seim, Board member
- 46SEC EDGARBruce E. Scott, Board member
- 47SEC EDGARJoanne B. Bauer, Board member
- 48SEC EDGARMark W. Parrish, Board member
- 49SEC EDGARVance B. Moore, Board member
- 50SEC EDGARGary S. Petersmeyer, Board member
- 51SEC EDGARDonald C. Wegmiller, Board member
- 52SEC EDGARJoseph E. Whitters, Board member
- 53SEC EDGARJohn D. Stobo Jr., Board member
- 54SEC EDGARSara J. White, Board member
- 55SEC EDGARBrock Nelson, Board member
- 56SEC EDGARKevin L. Roberg, Board member
- 57SEC EDGARMary E. Foley, Board member
- 58SEC EDGARRandy D. Lindholm, Board member
- 59SEC EDGARWilliam H. Younger Jr., Board member
- 60SEC EDGARJames T. Judson, Board member
- 61SEC EDGARCorey J. Manley, General counsel
- 62SEC EDGARJohn Choma, General counsel
- 63SEC EDGARDan S. Johnston, General counsel
- 64SEC EDGARResults of operations
- 65SEC EDGARExecutive or director change
- 66
- 67SEC EDGARResults of operations
- 68SEC EDGARResults of operations
- 69SEC EDGARRegulation FD disclosure
- 70SEC EDGARResults of operations
- 71SEC EDGARBylaws or fiscal year changed
- 72SEC EDGARExecutive or director change
- 73SEC EDGARResults of operations
- 74SEC EDGARExecutive or director change
- 75
- 76NasdaqNasdaq calendar
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87